CommercialPrior AuthMedium impact
Penpulimab-kcqx (CPB 1080, reviewed 2026-04-15)
Aetna·Oncology, Hematology·Medical Policy
Effective date
Apr 15, 2026
We identified it
Aug 13, 2026
Summary
Aetna has established new coverage criteria for penpulimab-kcqx (CPB 1080), a PD-1 blocking antibody approved for nasopharyngeal carcinoma and appendiceal neoplasms. Precertification is now required for all claims, with specific dosing protocols (200 mg IV every 3 weeks or every 2 weeks depending on indication) and a maximum 24-month treatment duration. Patients with prior disease progression on PD-1/PD-L1 inhibitors are excluded from coverage.
Action Required
Immediately upon implementation (by 2026-04-15): (1) Billing team must configure system to require precertification for all penpulimab-kcqx claims submitted to Aetna commercial plans before claims are processed—contact (866) 752-7021 or fax (888) 267-3277 for prior authorization; (2) Update encounter forms and templates to indicate that penpulimab-kcqx requires Statement of Medical Necessity (SMN) precertification forms (available through Specialty Pharmacy Precertification); (3) Providers must document one of the approved indications: NPC non-keratinizing (first-line combination therapy OR single-agent post-platinum progression) OR appendiceal neoplasm with dMMR/MSI-H or POLE/POLD1 mutation; (4) Coding/billing staff must verify patient does NOT have prior disease progression on PD-1/PD-L1 inhibitors before submission—such patients are excluded; (5) Ensure claims include appropriate site of care documentation per Utilization Management Policy on Site of Care for Specialty Drug Infusions; (6) Program system to deny or request reauthorization after 24 months of cumulative therapy. Failure to obtain precertification will result in claim denials.